European Medicines Agency

Doc. Ref. EMEA/162839/2009
P/41/2009

EUROPEAN MEDICINES AGENCY DECISION

of 23 March 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for cannabidiol, delta-9-tetrahydrocannabinol (EMEA-000181-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

DISCLAIMER: This Decision does not entitle to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006, as amended.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 23 March 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for cannabidiol, delta-9-tetrahydrocannabinol (EMEA-000181-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by GW Pharma Ltd on 7 March 2008 under Article 16(1) of Regulation (EC) No 1901/2006 as amended also requesting a deferral under Article 20 of said Regulation,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 February 2009, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 21 of said Regulation**,**

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a Paediatric Investigation Plan and on the granting of a deferral,

(2) It is therefore appropriate to adopt a Decision granting a Paediatric Investigation Plan,

(3) It is therefore appropriate to adopt a Decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for cannabidiol, delta-9-tetrahydrocannabinol, oromucosal spray, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for cannabidiol, delta-9-tetrahydrocannabinol, oromucosal spray, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to GW Pharma Ltd, Porton Down Science Park, Salisbury, Wiltshire, SP4 0JQ, United Kingdom.

Done at London, 23 March 2009

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref. EMEA/PDCO/56473/2009
EMEA-000181-PIP01-08

OPINION OF THE PAEDIATRIC COMMITTEE ON THE AGREEMENT OF A PAEDIATRIC INVESTIGATION PLAN AND A DEFERRAL

Scope of the application

Active substance:
Cannabidiol, delta-9-tetrahydrocannabinol

Condition(s):
Spasticity

Pharmaceutical form(s):
Oromucosal spray

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
GW Pharma Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, GW Pharma Ltd submitted for agreement to the EMEA on 7 March 2008 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 31 July 2008.

Supplementary information was provided by the applicant on 28 November 2008.

A meeting with the Paediatric Committee took place on 4 February 2009.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,

- to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex and appendix.

London, 6 February 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN

PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

Spasticity

- **Proposed PIP indication**

Intractable spasticity due to cerebral palsy or traumatic CNS injury.

- **Subset(s) of the paediatric population concerned by the paediatric development**

From 0 to less than 18 years.

- **Formulation(s)**

Oromucosal spray for oral use.

- **Studies**

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	2	1. Double blind, randomized multicenter, placebo controlled trial to evaluate efficacy, safety and pharmacokinetics of cannabidiol, delta-9-tetrahydrocannabinol as an add-on treatment in children from 8 to less than 18 years of age with intractable spasticity due to cerebral palsy or traumatic CNS injury. 2. Double blind, randomized multicenter, placebo controlled trial to evaluate efficacy, safety and pharmacokinetics of cannabidiol, delta-9-tetrahydrocannabinol as an add-on treatment in children less than 8 years of age with intractable spasticity due to cerebral palsy or traumatic CNS injury.

Measures to address long term follow-up of potential safety issues or efficacy in relation to paediatric use:	**No**
Date of completion of the paediatric investigation plan:	**December 2015**
Deferral for some or all studies contained in the paediatric investigation plan:	**Yes**